indazoles has been researched along with Paraganglioma in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Auchus, RJ; Bible, KC; Burton, JK; Harris, P; Jasim, S; Jimenez, C; Sideras, K; Suman, VJ; Worden, FP | 1 |
| Brock, P; Dillhoff, M; Espinosa, A; Kirschner, LS; Konda, B; Owen, D; Patel, S; Phay, J; Schmidt, CR; Shah, MH; Shirley, L | 1 |
1 trial(s) available for indazoles and Paraganglioma
| Article | Year |
|---|---|
Phase II trial of pazopanib in advanced/progressive malignant pheochromocytoma and paraganglioma.
Topics: Adrenal Gland Neoplasms; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Disease-Free Survival; Electrocardiography; Endocrine Gland Neoplasms; Female; Humans; Indazoles; Male; Middle Aged; Paraganglioma; Pheochromocytoma; Protein Kinase Inhibitors; Pyrimidines; Receptors, Vascular Endothelial Growth Factor; Sulfonamides; Treatment Failure | 2017 |
1 other study(ies) available for indazoles and Paraganglioma
| Article | Year |
|---|---|
Favorable and Durable Response to Pazopanib in Metastatic Refractory Paraganglioma.
Topics: Angiogenesis Inhibitors; Biopsy; Humans; Indazoles; Male; Middle Aged; Paraganglioma; Pyrimidines; Retroperitoneal Neoplasms; Sulfonamides; Tomography, X-Ray Computed; Treatment Outcome | 2017 |